Drug reference

trilaciclib

CDK4/6 kinase inhibitor · Myelosuppression prevention

CDK4/6 kinase inhibitorMyelosuppression prevention

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

FDA category + note

Mechanism

Trilaciclib is a CDK4/6 kinase inhibitor that transiently maintains immune cells and hemopoietic stem and progenitor cells in G1 cell cycle arrest to reduce bone marrow toxicity of chemotherapy.

Indications

decrease the incidence of chemotherapy-induced myelosuppression in patients receiving a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer